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A B S T R A C T
Flow cytometry immunophenotyping (FCI) has an important role in the clinic work-up of fine needle aspirates (FNAs)
of lymph nodes. Its standardization has been defined by proposed analytical protocols and procedures used to assure
proper analytical results also in those non-routine samples. In Institute of Clinical Chemistry, »Merkur« University Hos-
pital, FCI is accredited method according to laboratory accreditation standard ISO 15189. According to this laboratory
accreditation standard, participation in external quality assessment (EQA) programs is a prerequisite for assuring in-
tegrity and quality of the entire laboratory process. A critical analysis of our institutional experience in the feasibility of
FCI of the material obtained by FNA of lymph nodes with suspected lymphoma represented the purpose of the study. Dur-
ing an eight-year period in Institute of Clinical Chemistry, »Merkur« University Hospital, a total of 1295 FNA analysis
was done, 245 of them with a possible diagnosis of B-cell Non-Hodgkin lymphomas (B-NHL) formed the basis of the
study. Lymphocytes were isolated on density gradient according to Boyum et al. The average feasibility of FNAs for FCI
analysis was 86 % (ranged 78–93%). An acceptable total cell number in FNAs for FCI analysis (4257) was established. In
total population of respondents statistical significances in expressions of cellular antigens CD3, CD5, CD22, CD23,
CD19 and CD5 on B-cells (CD5+CD19+) between patient´s with final diagnosis of benign, reactive lymphoid prolifera-
tions and patient´s with diagnosis of B-NHL were found. EQA results analysis showed that all results were either inside
target values (X±1SD) or inside accepted values (X±2SD). Compatibility of the restriction of imunoglobulins light chains
determinated by FCI and cytomorphology diagnosis depends on the choice of criterion values of the light chains ratio
which determine the monoclonality. According to the matrix of shares of all classified data of retained neural network,
ranges of diagnostic sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and pre-
valency of 82%, 72%, 93%, 48%, and 72% were produced. As a conclusion, FCI is a reliable methodology for phenotyping
FNAs of lymph nodes with suspected B-NHLs detecting their clonality easily.
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Introduction
Flow cytometry immunophenotyping (FCI) as a fast,
objective and quantitative multiparametric method has
become the preferred method for the lineage assignment,
detection of clonality and aberrant antigen coexpression,
as well as for quantitation of malignant cells. It is based
on the determination of various cell differentiation (CD)
markers that form a specific immunophenotypic antigen
profile of cell lineage and its maturation stage of every
single cell in specimen, but can Nalso detect monoclonal
B-cell populations that by cytomorphology may be inter-
preted as reactive. High morphological similarity of be-
nign lymphoproliferative lesions (reactive lymphoid pro-
liferations) and Non-Hodgkin´s lymphomas (NHLs)
requires FCI as essential ancillary technique to cyto-
morphology to their differential diagnosis. FCI is usually
performed, but not limited, on routine specimens such as
359
Received for publication June 19, 2009
peripheral blood (PB) or bone marrow (BM) aspirates. In
Institute of Clinical Chemistry, »Merkur« University
Hospital, FCI of lymphoid cells is accredited method ac-
cording to laboratory accreditation standard ISO 15189,
even in non-routine samples which include liquor, asci-
tes/pleural effusions or solid tissue (lymph nodes). A sin-
gle cell suspension preparation is crucial. Paradoxically,
FCI is rarely performed on cytological specimens which
are cell suspensions, such as fine-needle aspirates (FNAs),
and therefore ideal for FCI. Analytical protocols and pro-
cedures are proposed and used as a part of FCI standard-
ization for ruling out the most common sources of varia-
bility1-5. The rare submitting of FNAs for FCI dictates
that every attempt should be made to assure proper ana-
lytical result and an objective, useful result interpreta-
tion6,7. Today only a few reports describe FCI performed
in FNAs as rare, »non-routine« specimen8–17. The pur-
pose of the study was a critical analysis of our insti-
tuional experience in the feasibility of FCI of the mate-
rial obtained by FNAs of lymph nodes with suspected
B-NHL.
Materials and Methods
During an eight-year period (2000–2008) in Institute
of Clinical Chemistry, »Merkur« University Hospital, a
total of 1295 FNA analysis was done. In the final cohort
245 of them (128 men and 117 women) with a possible di-
agnosis of B-NHL formed the basis of the study. At each
FNA 5–10 passes in the lymph node were completed.
Each FNA was obtained using a new 23 gauge disposable
needle and 10 ml syringe as heterogeneous cell suspen-
sions. Lymphocytes were isolated on density gradient ac-
cording to Boyum et al. The absolute number of leuko-
cytes was established on a Sysmex-XE 2100 hematologic
analyzer. All patients samples and clinical details were
obtained upon receiving patients consent and the ethical-
committee approval. The reference diagnosis was ob-
tained by standard cytological and histological methods17.
In internal quality control validity of flow cytometer op-
tical alignment and fluidics system (FlowCheck Fluoro-
spheres; Coulter PN 6605359), quality of reagents, ery-
throcytes lysis procedure and cell staining (Immuno-Trol
Cells Kit, Coulter, PN 6607077), quality of monoclonal
antibodies (Cyto-TrolTM Control Cells Kit, Coulter, PN
6604248) and specific analytical conditions were deter-
mined. The FCI analysis of cellular antigens was done
using directly fluorochrome-conjugated monoclonal anti-
bodies in simultaneous dual- or three- color immuno-
fluorescence: CD45 (DAKO F0861), CD14 (DAKO R0864;),
CD3 (DAKO C7067), CD19 (DAKO C7066), CD5 (DAKO
F0795), CD23 (DAKO R7108), CD10 (DAKO R0848),
CD20 (DAKO F0799), CD22 (DAKO R7061), CD24
(DAKO F7134), CD38 (DAKO F7101), CD138 (DAKO
R7229), FMC 7 (DAKO F7110), KAPPA (DAKO F0434),
LAMBDA (DAKO R0437). Fixation and whole blood lysis
of FNAs was done (Coulter Q-PREP, Q-PREP/Immu-
noPrep Reagent System PN 7546946) before quadrant
analysis on instrument (Coulter EPICS- XL, System IITM
Software, Coulter Corporation, Miami, Florida). Lym-
phocyte gate was set by forward light scatter (FS) and
side scatter (SS) and validated by CD45 and CD14 mo-
noclonal antibodies. For greater precision in identifica-
tion of lymphocyte subsets quadrant analysis based on
coexpression of antigens defined by dual- or three- color
combinations was used17. Standardized analytical proto-
cols and procedures assured validity of FCI process. In
daily internal quality control validity of flow cytometer
optical alignment parameters (CV FS, CV FL1, CV FL2,
CV FL3 and CV FL4) all parameters were inside target
value (2.00)(CV FS 1.81; CV FL1 0.91; CV FL2 0.99; CV
FL3 1,13; CV FL4 1.20) and all were acceptable with
5.4–10.0% accuracy. According to laboratory accredita-
tion standard ISO 15189 participation in external quality
assessment (EQA) programs is a prerequisite for assur-
ing integrity and quality of the entire laboratory process.
Therefore analytical results were confirmed by participa-
tion in EQA program CEQUAL organized by Becton
Dickinson (Germany). CEQUAL analysis of cellular lym-
phocyte antigens was done by own directly fluorochro-
me-conjugated monoclonal antibodies according to own
laboratory procedure and according to the method and
procedure of Becton Dickinson (BD). EQA results analy-
sis showed that all results were either inside target val-
ues (X±1SD for CD19, CD3, CD16+CD56+, CD3+
CD8+, CD3+HLAD/DR+) or inside accepted values (X ±
2SD for CD3 and CD3+CD4+).
In statistics data analysis multivariate statistical me-
thod (neural network) was used because of complex sys-
tem with a large number of measured parameters.
Results
From a total of 1295 FNAs the average feasibility for
FCI analysis was 86% (ranged 78 – 93%) (Figure 1). The
quality of lymphocytes obtained by FNA as a material for
FCI was very satisfactory. In total population of respon-
dents (128 men, 117 woman) there was no statistical sig-
nificance in age (p=0.05), but a statistical significance in
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Fig. 1. The FNAs average feasibility for FCI analysis during an
eight-year period (2000–2008).
age between patient's with final diagnosis of benign, re-
active lymphoid proliferations and patient´s with diag-
nosis of B-NHL (p=0.00) was found.
Analytical evaluation
Based on the parameters of cell size (FS) and granu-
larity (SS), a homogeneous specific cell population (popu-
lation size of lymphocytes) was isolated from a heteroge-
neous cell suspension. A minimum acceptable total cell
number in FNAs for FCI analysis was established through
linear regression of cell number on a homogeneous spe-
cific cell population (population size of lymphocytes) on
the measuring instrument (Coulter EPICS-XL) and an
absolute lymphocyte number (x109/L) on referral instru-
ment (Sysmex XE-2100) (Figure 2). Minimal absolute
lymphocyte number on referral instrument (0.24x109/L)
positively corresponded (r=0.93) with total number of
cells on a homogeneous specific cell population (popula-
tion size of lymphocytes) and therefore lower linearity
level was equal to the minimum acceptable total cell
number in FNAs needed for FCI analysis (4257 cells).
Daily control of measuring instrument performance was
consistent with the measurement criteria established at
instrument setup (Figure 3). Measuring instrument pre-
cision calculated as variation coefficients (CV) of all pa-
rameters (FSmean channel, AUX (FL3), FL1 mean channel, FL2
mean channel, FL3 mean channel, FL4 mean channel) with half peak
variation coefficients of all parameters (HPCVFS,
HPCVFL1, HPCVFL2, HPCVFL3, HPCVFL4) were within
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Fig. 2. Corellation of parameters of the refferal instrument (Sys-
mex XE-2100) and the measuring instrument (Coulter EPICS-
-XL); Sysmex XE-2100 – absolute lymphocyte number (x109/L) on
the referral instrument (Sysmex XE-2100); Coulter EPICS-XL –
cell number (N) on a homogeneous specific cell population (popu-
lation size of lymphocytes) on the measuring instrument (Coulter
EPICS-XL)
Fig. 3. Daily control of optical alignment and fluidics system on
measuring instrument (Coulter EPICS-XL). Levy-Jennings gra-
phic of half peak variation coefficients (HPCV) of all parameters.
TABLE 1
STATISTICAL SIGNIFICANCES IN EXPRESSIONS OF CELLULAR ANTIGENS BETWEEN PATIENT´S WITH FINAL DIAGNOSIS OF BENIGN,
REACTIVE LYMPHOID PROLIFERATIONS AND PATIENT'S WITH DIAGNOSIS OF B-NHL (KRUSKALL-WALLIS TEST; STATISTICAL
SIGNIFICANCE p<0.05)
Cellular
antigen (CD)
Cellular expression (Median %) Statistical significance (p)
(p<0.05)Benign, reactive lymphoid proliferations B-NHL
CD3 55.3 31.4 0.000
CD5 45.9 22.7 0.000
CD20 29.7 63.7 0.001
CD22 50.8 44.6 0.532 (NS)
CD23 15.8 42.1 0.000
CD19 31.5 61.9 0.000
CD38 31.0 60.0 0.000
CD5+CD19+ 1.6 53.4 0.000
NS – not statistically significant
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Fig. 4 (a-d). Linearity of the flow cytometry immunophenotyping (FCI). Relative lymphocytes number (%) on measuring instrument
(Coulter EPICS-XL): a) in a sample with normal leucocyte number and b) samples diluted with PBS buffer: a) the ratio of 1:5, c) the ra-
tio of 1:10 and d) the ratio of 1:50.
TABLE 2
COMPARISON OF CYTOMORPHOLOGY DIAGNOSIS AND RESTRICTION OF IMUNOGLOBULINS LIGHT CHAINS DETERMINATED BY
FLOW CYTOMETRY IMMUNOPHENOTYPING (FCI) ACCORDING TO THE CHOICE OF BOUNDARY VALUES OF THE RATIO OF LIGHT
CHAINS WHICH DETERMINE THE RESTRICTION
Cytomorphology
(N=237)
restriction of imunoglobulins light chains determinated by FCI (kappa or lambda type)
Negative Positive
Criterion values of the ratio of light chains
kappa3 lambda
lambda 1kappa
kappa5.5 lambda
lambda1.4 kappa
kappa3 lambda
lambda1 kappa
kappa5.5 lambda
lambda1.4 kappa
Benign, reactive lymphoid
proliferations (N=9)
12
(5.0%)
23
(9.7%)
37
26
B-NHL
(N=59)
19
28
140
(59.0%)
131
(55.3%)
Other neoplasms
(N=29)
6
(20.7%)
10
(34.5%)
23
(79.3)
19
(65.5%)
the acceptable range (1.12–1.98) as well as instrument
accuracy calculated as absolute bias of all parameters
(1.9–2.0). Accuracy of all measured parameters on Coul-
ter EPICS-XL was within the acceptable limits of devia-
tion for the measuring instrument (±10%):0–1% for rela-
tive number of lymphocytes, 7–7.5% for absolute lympho-
cytes number and 7–8% for total number of cells on a ho-
mogeneous specific cell population (population size of
lymphocytes). Linearity of the FCI in diluted sample
(PBS buffer) with the ratio of 1:50 was followed by
non-linear downregulation of relative lymphocyte num-
ber (Figure 4 a-d).
Clinical evaluation
The final diagnosis of benign, reactive lymphoid pro-
liferations or B-NHL was obtained by standard cytologi-
cal and histological methods. In total population of re-
spondents statistical significances in expressions of cellu-
lar antigens CD3, CD5, CD22, CD23, CD19 and CD5 on
B-cells (CD5+CD19+) between patient´s with final diag-
nosis of benign, reactive lymphoid proliferations and pa-
tient´s with diagnosis of B-NHL were found (Table 1).
The ratio of imunoglobulins light chains was defined as
percentage of the dominant type of imunoglobulins light
chain divided by the percentage of non-dominant type of
imunoglobulins light chain on B lymphocytes (CD19+).
Equivalent areas under the Receiver-Operating Charac-
teristic curves (ROC – curves) (0.73 kappa/ lambda com-
pared to 0.74 lambda/kappa) confirmed the identical di-
agnostic value of both imunoglobulins light chain ratios
in differentiation of benign, reactive lymphoid prolifera-
tions and B-NHLs. Comparison of the restriction of
imunoglobulins light chains determinated by FCI and
cytomorphology diagnosis showed that their compatibil-
ity depends on the choice of criterion values of the light
chains ratio which determine the restriction (Table 2).
Diagnostic sensitivity (82%), specificity (72%), positive
predictive value (PPV, 93%), negative predictive value
(NPV, 48%) and prevalence (72%) for FCI was calculated
according to the matrix of shares of all classified data of
retained neural network (Table 3).
Discussion and Conclusion
Flow cytometry immunophenotyping (FCI) as a fast,
objective and quantitative multiparametric method con-
tributes to diagnosis, classification and monitoring of
various hematological diseases (leukemias, lymphomas,
myelomas). Today, leukemia and lymphoma immuno-
phenotyping represents an extremely important comple-
ment to cytomorphology in the diagnosis and monitoring
of hematopoietic malignancies, because of data that form
a specific immunophenotypic antigen profile of cell lin-
eage and its maturation stage8–22,52. Sample preparation
for FCI analysis must consider the type of specimen sub-
mitted and the number of cells available for analysis. Pe-
ripheral blood, bone marrow or tissue specimens should
be processed to contain a suspension of the cells of inter-
est at a concentration optimal for monoclonal staining23.
Although cytological specimens, such as FNAs, are cell
suspensions and therefore ideal material for FCI, they
are rarely used for FCI, because of the problem to obtain
ideal number of 10000 cells in a tube for FCI analysis
(cells concentration in the sample » 0.5–5.0x106/mL)9. In-
sufficient number of cells could be a consequence of inad-
equate or poor FNAs of lymph node, as well as selective
cells loss during the cell preparation process23. It has
been proved, however, that the quality of FNAs of lymph
nodes depends on the appropriate leukocyte number in
analytical sample, achievement that is more a rule than
an exception35.
In order to evaluate the usefulness of FNAs for FCI
analysis, we critically analysed and reviewed our institu-
tional experience in the feasibility of FCI of all FNAs
submitted to our Flow unit during an eight-year period
(2000–2008). It is evident that during this period the per-
cent of adequate FNAs for FCI constantly increases dur-
ing the years indicating better experience in sampling
and aspirations of lymph nodes. The high feasibilities of
FNAs for FCI analysis ranged from 78 to 93% during the
entire period proved that FNAs are an appropriate mate-
rial for FCI analysis. FCI linearity lime (0.35x109/L leu-
cocytes in the sample) is a part of the literature of
well-known range of acceptable leukocytes number in
FNAs of lymph nodes31–33. Unacceptable FNAs samples
had a leucocytes number less than acceptable, and the
conclusion about lowest linearity limit of the FCI (0.24x
109/L) as an acceptable cell number in FNAs of lymph
nodes (4075 cells) was confirmed in the literature (5000
cells per sample required for FCI analysis)32,33,36,37.
Over the years, standardization of FCI technique has
lead to improvements in performing FCI analysis. In at-
tempts to assist with standardization, the United States-
-Canadian Consensus and The National Committee for
Clinical Laboratory Standards (NCCLS) guidelines pro-
vided recommendations for FCI in hematopathology, but
each laboratory is ultimately responsible for validating
its own procedures7,27–30. The United States-Canadian
Consensus guidelines strongly recommend that every at-
tempt should be made to derive useful information from
any specimen submitted27. Each specimen must be con-
sidered a unique case and that is why for FCI analysis
preparation of a single cell suspension is crucial. FCI
analysis and the data interpretation rely on standardiza-
tion and validation of the measuring instrument, the re-
agents and the procedure34,51. In our laboratory valida-
tion of measuring instrument and daily validation of its
optical alignment and fluidics system was assessed with
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TABLE 3
MATRIX OF SHARES OF ALL CLASSIFIED DATA OF RETAINED
NEURAL NETWORK
Benign, reactive lym-
phoid proliferations
B-NHL
Benign, reactive lym-
phoid proliferations
18 21
B-NHL 7 95
FlowCheck Fluorospheres (uniformly sized beads run at
a constant PMT voltage on a daily basis), whereas the re-
agents were validated with Immuno-Trol Cells Kit, and
the procedure with Cyto-TrolTM Control Cells Kit. The
mean forward scatter (FS) and side scatter (SS) channel
numbers and percent of variation coefficients (% CV)
were recorded. The acceptable ranges for each parameter
were established by first running the beads 20 times over
a 5 day time period at the same PMT setting. Levy–
Jennings graphs were then used to plot the daily ob-
tained values.
The advantage of FCI regarding cytomorphology is
the possibility to detect monoclonal B-cell populations
that by cytomorphology may be interpreted as reactive,
based on morphologically relatively unique population of
lymphocytes19,24–26. Dual- or three-color combinations of
monoclonal antibodies (MoAb) and setting an electronic
gate only around specific cell population (lymphocytes)
has established better determination of imunoglobulins
light chain expression, while the simultaneous expres-
sion of two or more antigens (coexpression) or cell size on
specific cell population (lymphocytes) indicated changed
immunophenotype of B cells38–40. The increased number
of B lymphocytes in the benign, reactive lymphoid prolif-
erations could suggest the existence of an immune re-
sponse involving interactions between T and B cells41. In
the literature there are specified limit values of the im-
munoglobulin light chains ratio to set monoclonality
(kappa/lambda, lambda/kappa) from 1.4 to 6.0, but only
few papers have explored the diagnostic importance of
their determination42–47. The ratio of immunoglobulins
light chains kappa/lambda less than 0.7 or greater than
5.5 in references is proven as optimal for distinguishing
malignant lymphomas of benign, reactive lymphoid pro-
liferations42. Therefore, this criterion values were also
used in this paper. According to them, compatibility of
cytomorphology diagnosis and restriction of imunoglo-
bulins light chains determinated by flow cytometry im-
munophenotyping (FCI) is 55.3% (57.1% Ibrahim I et al,
1989)48. In 23 samples (9.7%) a negative outcome of both
methods was established. Within the group of cytomor-
phology benign, reactive lymphoid proliferations of un-
known origin (N=49), in 26 of them (53.1%) the restric-
tion of imunoglobulins light chains was observed consis-
tent with the known literature value of 63%47. By apply-
ing a stronger criteria for monoclonality (kappa>5.5
lambda; lambda>1.4 kappa) the numbers of cytomor-
phology benign, reactive lymphoid proliferations of un-
known origin (26 instead of 37) and cytomorphology
B-NHLs (131 instead of 140) reduced. That is why sensi-
tivity decreased, but specificity and reliability of FCI in-
creased. Setting clear monoclonality criteria is difficult
due to sample heterogeneity49,50.
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IMUNOFENOTIPIZACIJA UZORAKA DOBIVENIH CITOLO[KOM PUNKCIJOM LIMFNOG ^VORA
METODOM PROTO^NE CITOMETRIJE
S A @ E T A K
Imunofenotipizacija metodom proto~ne citometrije ima va`nu ulogu u diferencijalnoj dijagnostici limfadenopatija.
Standardizacija metode proto~ne citometrije podrazumijeva kori{tenje predlo`enih analiti~kih protokola i procedura
koji osiguravaju pouzdanost analiti~kih rezultata i u uzoraka koji nisu rutinski. U Zavodu za klini~ku kemiju Klini~ke
bolnice »Merkur« imunofenotipizacija metodom proto~ne citometrije je akreditirana metoda prema HRN EN ISO 15189
»Medicinski laboratoriji – Posebni zahtjevi za kvalitetu i osposobljenost«. Svrha ovog rada je kriti~ka analiza imuno-
fenotipizacije ne-rutinskih uzoraka dobivenih citolo{kom punkcijom limfnog ~vora metodom proto~ne citometrije, a u
kojih je postojala sumnja na B stani~nu neoplazmu (B-NHL). Tijekom osmogodi{njeg razdoblja u Klini~koj bolnici
»Merkur« ukupno je u~injeno 1295 citolo{kih punkcija limfnog ~vora, od toga je 245 uzoraka punktata limfnog ~vora u
kojih je postavljena sumnja na B-NHL imunofenotipizirano metodom proto~ne citometrije. Limfociti su izdvojeni na
gradijentu gusto}e (metoda Boyuma i sur.). Odre|ena je prosje~na prihvatljivost uzoraka punktata limfnog ~vora za
imunofenotipizaciju metodom proto~ne citometrije (86%) koja je tijekom razdoblja iznosila od 78 do 93%, kao i pri-
hvatljiv broj stanica u uzorku punktata limfnog ~vora (4257 stanica). Analizom ekspresija stani~nih povr{inskih biljega
CD3, CD22, CD23, CD19 i CD5 pozitivnih limfocita B (CD5+CD19+) utvr|ena je statisti~ki zna~ajna razlika u eks-
presiji ovih biljega u benignih, reaktivnih limfadenopatija nepoznatog uzroka i u B-NHL. Podudarnost citomorfolo{ke i
imunofenotipizacijske dijagnoze ovisila je o odabiru grani~nih vrijednosti omjera lakih lanaca imunoglobulina koji od-
re|uju monoklonalnost. Prema matrici udjela svih klasificiranih podataka zadr`ane neuronske mre`e izra~unate su
dijagnosti~ka osjetljivost (82%), specifi~nost (72%), pozitivna prediktivna vrijednost (PPV, 93%), negativna prediktivna
vrijednost (NPV, 48%) i prevalencija (72%) metode proto~ne citometrije. U zaklju~ku, metoda proto~ne citometrije je
pouzdana metoda za imunofenotipizaciju uzoraka punktata limfnog ~vora, a u kojih je postavljena sumnja na B sta-
ni~nu neoplazmu (B-NHL).
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